Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients

Giuseppe Derosa, Pamela Maffioli, Ilaria Ferrari, Ilaria Palumbo, Sabrina Randazzo, Elena Fogari, Angela D'Angelo, Arrigo F G Cicero

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

We planned a randomized, double blind clinical trial to evaluate whether an antihypertensive intervention at the proximal or distal level of the renin-angiotensin-aldosterone system could have different effects on a broad range of innovative cardiovascular risk biomarkers. A total of 288 hypertensive Caucasian patients (115 men and 113 women), aged 18 years, were enrolled in this study. They were randomized to take losartan 50 mg per day or ramipril 5 mg per day for 1 month and titrated up to 100 mg per day and 10 mg per day for 13 months, respectively. At baseline, 1, 2 and 14 months after therapy initiation, we evaluated the following parameters: body weight, body mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting plasma glucose (FPG), M-value, adiponectin (ADN), resistin (r), retinol binding protein-4 (RBP-4), visfatin, vaspin, high-sensitivity C-reactive protein (Hs-CRP), matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9). No variation of body weight, BMI, FPG or vaspin was obtained with either treatment. We recorded a similar improvement in SBP, DBP and Hs-CRP with both treatments; however, losartan also increased M-value, ADN and visfatin, whereas ramipril did not. Furthermore, losartan decreased r, RBP-4, MMP-2 and MMP-9, whereas ramipril did not have any effect on these parameters. In conclusion, we observed that short-term treatment with losartan improved several metabolic parameters (M-value, ADN, RBP-4, r and visfatin) and decreased vascular remodeling biomarkers (MMP-2 and MMP-9) in hypertensive subjects, whereas ramipril did not.

Original languageEnglish
Pages (from-to)145-151
Number of pages7
JournalHypertension Research
Volume34
Issue number1
DOIs
Publication statusPublished - Jan 2011

Fingerprint

Ramipril
Losartan
Adipose Tissue
Biomarkers
Blood Pressure
Nicotinamide Phosphoribosyltransferase
Retinol-Binding Proteins
Matrix Metalloproteinase 2
Adiponectin
Matrix Metalloproteinase 9
C-Reactive Protein
Fasting
Body Mass Index
Body Weight
Resistin
Glucose
Vascular Remodeling
Therapeutics
Renin-Angiotensin System
Antihypertensive Agents

Keywords

  • adipokines
  • losartan
  • matrix metalloproteinases
  • ramipril

ASJC Scopus subject areas

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients. / Derosa, Giuseppe; Maffioli, Pamela; Ferrari, Ilaria; Palumbo, Ilaria; Randazzo, Sabrina; Fogari, Elena; D'Angelo, Angela; Cicero, Arrigo F G.

In: Hypertension Research, Vol. 34, No. 1, 01.2011, p. 145-151.

Research output: Contribution to journalArticle

@article{772b66399c3940b884a40e0983a64f57,
title = "Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients",
abstract = "We planned a randomized, double blind clinical trial to evaluate whether an antihypertensive intervention at the proximal or distal level of the renin-angiotensin-aldosterone system could have different effects on a broad range of innovative cardiovascular risk biomarkers. A total of 288 hypertensive Caucasian patients (115 men and 113 women), aged 18 years, were enrolled in this study. They were randomized to take losartan 50 mg per day or ramipril 5 mg per day for 1 month and titrated up to 100 mg per day and 10 mg per day for 13 months, respectively. At baseline, 1, 2 and 14 months after therapy initiation, we evaluated the following parameters: body weight, body mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting plasma glucose (FPG), M-value, adiponectin (ADN), resistin (r), retinol binding protein-4 (RBP-4), visfatin, vaspin, high-sensitivity C-reactive protein (Hs-CRP), matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9). No variation of body weight, BMI, FPG or vaspin was obtained with either treatment. We recorded a similar improvement in SBP, DBP and Hs-CRP with both treatments; however, losartan also increased M-value, ADN and visfatin, whereas ramipril did not. Furthermore, losartan decreased r, RBP-4, MMP-2 and MMP-9, whereas ramipril did not have any effect on these parameters. In conclusion, we observed that short-term treatment with losartan improved several metabolic parameters (M-value, ADN, RBP-4, r and visfatin) and decreased vascular remodeling biomarkers (MMP-2 and MMP-9) in hypertensive subjects, whereas ramipril did not.",
keywords = "adipokines, losartan, matrix metalloproteinases, ramipril",
author = "Giuseppe Derosa and Pamela Maffioli and Ilaria Ferrari and Ilaria Palumbo and Sabrina Randazzo and Elena Fogari and Angela D'Angelo and Cicero, {Arrigo F G}",
year = "2011",
month = "1",
doi = "10.1038/hr.2010.205",
language = "English",
volume = "34",
pages = "145--151",
journal = "Hypertension Research",
issn = "0916-9636",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients

AU - Derosa, Giuseppe

AU - Maffioli, Pamela

AU - Ferrari, Ilaria

AU - Palumbo, Ilaria

AU - Randazzo, Sabrina

AU - Fogari, Elena

AU - D'Angelo, Angela

AU - Cicero, Arrigo F G

PY - 2011/1

Y1 - 2011/1

N2 - We planned a randomized, double blind clinical trial to evaluate whether an antihypertensive intervention at the proximal or distal level of the renin-angiotensin-aldosterone system could have different effects on a broad range of innovative cardiovascular risk biomarkers. A total of 288 hypertensive Caucasian patients (115 men and 113 women), aged 18 years, were enrolled in this study. They were randomized to take losartan 50 mg per day or ramipril 5 mg per day for 1 month and titrated up to 100 mg per day and 10 mg per day for 13 months, respectively. At baseline, 1, 2 and 14 months after therapy initiation, we evaluated the following parameters: body weight, body mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting plasma glucose (FPG), M-value, adiponectin (ADN), resistin (r), retinol binding protein-4 (RBP-4), visfatin, vaspin, high-sensitivity C-reactive protein (Hs-CRP), matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9). No variation of body weight, BMI, FPG or vaspin was obtained with either treatment. We recorded a similar improvement in SBP, DBP and Hs-CRP with both treatments; however, losartan also increased M-value, ADN and visfatin, whereas ramipril did not. Furthermore, losartan decreased r, RBP-4, MMP-2 and MMP-9, whereas ramipril did not have any effect on these parameters. In conclusion, we observed that short-term treatment with losartan improved several metabolic parameters (M-value, ADN, RBP-4, r and visfatin) and decreased vascular remodeling biomarkers (MMP-2 and MMP-9) in hypertensive subjects, whereas ramipril did not.

AB - We planned a randomized, double blind clinical trial to evaluate whether an antihypertensive intervention at the proximal or distal level of the renin-angiotensin-aldosterone system could have different effects on a broad range of innovative cardiovascular risk biomarkers. A total of 288 hypertensive Caucasian patients (115 men and 113 women), aged 18 years, were enrolled in this study. They were randomized to take losartan 50 mg per day or ramipril 5 mg per day for 1 month and titrated up to 100 mg per day and 10 mg per day for 13 months, respectively. At baseline, 1, 2 and 14 months after therapy initiation, we evaluated the following parameters: body weight, body mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting plasma glucose (FPG), M-value, adiponectin (ADN), resistin (r), retinol binding protein-4 (RBP-4), visfatin, vaspin, high-sensitivity C-reactive protein (Hs-CRP), matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9). No variation of body weight, BMI, FPG or vaspin was obtained with either treatment. We recorded a similar improvement in SBP, DBP and Hs-CRP with both treatments; however, losartan also increased M-value, ADN and visfatin, whereas ramipril did not. Furthermore, losartan decreased r, RBP-4, MMP-2 and MMP-9, whereas ramipril did not have any effect on these parameters. In conclusion, we observed that short-term treatment with losartan improved several metabolic parameters (M-value, ADN, RBP-4, r and visfatin) and decreased vascular remodeling biomarkers (MMP-2 and MMP-9) in hypertensive subjects, whereas ramipril did not.

KW - adipokines

KW - losartan

KW - matrix metalloproteinases

KW - ramipril

UR - http://www.scopus.com/inward/record.url?scp=78650916745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650916745&partnerID=8YFLogxK

U2 - 10.1038/hr.2010.205

DO - 10.1038/hr.2010.205

M3 - Article

VL - 34

SP - 145

EP - 151

JO - Hypertension Research

JF - Hypertension Research

SN - 0916-9636

IS - 1

ER -